Mike is a seasoned executive with over 25 years of experience in leading medical device companies and serving as a board member for several private and publicly traded life science companies. From 2010 to 2023 Mike served as CEO of Osprey Medical, an Interventional Cardiology commercial stage medical device company, publicly traded, and focused on technologies to reduce Contrast Induced Acute Kidney Injury. From 2003 to 2008, he was CEO of Anulex Technologies Inc., a private company focused on developing proprietary technologies to support the healing of spinal soft tissues that was successfully sold to Boston Scientific.  Prior to this Mike was President of Centerpulse Spine-Tech a publicly traded full line supplier of innovative spinal technologies. Mike was involved in the successful sale of Centerpulse Spine-Tech to Zimmer in the fall of 2003.  Early in his career Mike worked at Boston Scientific Scimed and Baxter Health Care where he served in a variety of sales and sales management roles.  Mike received his Bachelor of Business Administration, Business Management from The University of Texas at Austin.

Mike is a member of the Board of Directors of Nuwellis, Inc. Osprey Medical, Inc., and Formae, Inc.  Previous Board experience includes Chairman of OrthoCor Medical which was sold in 2019, Director Cardio Renal Society of America and Board of Anulex Technologies, Inc.

David has held executive product, technology, and organizational development leadership roles at several firms in the med tech sector. Most recently and for the last 7 years, he was Chief Technology Officer at Nuwellis (formerly CHF Solutions). Before Nuwellis, he served as the Vice President of Engineering at Senseonics, Inc. focusing on the development of an implantable glucose sensing system for the management of diabetes.  Prior to that, he was Chief Technology Officer at Biomedix where he led the company’s development of hardware, software, and web-based service solutions for the management of patients with vascular disease. David was a co-founder and board member of Biomedix and served as the VP of Engineering from 1997 to 2002.

David has also served as VP of Engineering and Technology for Image Sensing Systems, Inc. and Bosch/Telex Communications, Inc. where he directed technical activity at multiple domestic and international locations with a strong focus on employee development, innovation and on-time delivery. He is the recipient of multiple device patents and holds a BS in Electronics Engineering from the State University of New York as well as an MS in Management, and an MS in Medical Physics from the University of Minnesota.

John has over 45 years of experience in the medical device industry.  He has served as chief executive officer and board member of both public and private medical device firms.  Since 2012, John has served as board chairman of Nuwellis, Inc., a publicly traded medical device company focusing on returning patients to fluid balance.  Previously, he served as Nuwellis’ CEO and president from 2015 to 2020; served as president and chief executive officer of IntraTherapeutics, Inc., a medical device company involved in the manufacturing and distribution of peripheral vascular stents, from 1997 to 2001; and in various positions with, American Hospital Supply, Johnson & Johnson and Pfizer. John currently serves on the Board of Directors of Miromatrix, a public company developing bioengineered organs; is Chairman of the Board of IR Medtek, Inc, a private company focused on cancer detection; and is a member of the Board of Directors for Lymphatica Medtech, SA, a private company treating lymphatic diseases.  He previously served on the Board of Directors of Vascular Solutions (acquired by Teleflex in 2017), SenoRx, Inc. (acquired by CR Bard in 2010), and CryoCath Technologies (acquired by Medtronic in 2008).

John has a B.A. degree in Business Administration from California State University, Fullerton.

Nancy is the Principal at Ness & Associates, Inc., a financial consulting company founded in 1996. Nancy has been acting CFO for over 50 private and publicly traded healthcare companies, where her responsibilities have included raising equity, debt, and bridge financing, managing operating funds, human resources, budgets, financial forecast modeling, and tax returns. Nancy was CFO for Anulex Technologies from 2005-2010 and early in her career was an accountant at Northwest Airlines (Delta), and Home Styles Publishing and Marketing. 

Nancy earned a BA in Accounting and Business Administration from the University of St. Thomas and holds a Certified Public Accountant license.

 Dr. Prasad graduated from Louisiana State University School of Medicine in New Orleans in 2000. He completed Internal Medicine and Cardiology training at the University of Texas Southwestern at Dallas. Subsequently, he completed an Interventional Cardiology and an Endovascular Fellowship at the University of California San Diego. He then joined the faculty at UC San Diego and after three years moved back to Texas to join the faculty at UT Health Science Center at San Antonio. He is a Professor of Medicine and holds the Freeman Heart Association Endowment in Cardiovascular Disease. He also is the Director of the UT/UHS Heart and Vascular Institute Catheterization Laboratories at University Health System. His clinical interests are centered on the endovascular treatment of peripheral arterial disease including carotid and lower extremity disease, transcatheter aortic valve replacement, percutaneous ventricular support devices and complex high risk percutaneous coronary interventions. Dr. Prasad has a focus on Vascular Medicine, is also board certified by the American Board of Vascular Medicine, and holds a certification as a Registered Physician in Vascular Interpretation (RPVI).

He has served as the Associate Program Director and Program Director for the Cardiovascular Diseases Fellowship Program at UT Health San Antonio. He is the Director of the Interventional Cardiology Fellowship Program. In addition to an active role in Fellow training, Dr. Prasad is involved with clinical research. He is the PI on both investigator-initiated and industry-sponsored clinical trials. His areas of current interest include novel approaches to therapy for limb salvage and acute kidney injury following endovascular interventions. He is also involved with efforts to understand subclinical vascular disease in minority populations and serves as a co-investigator in the Cameron County Hispanic Cohort Study. The goals of this endeavor are to understand the prevalence, predictors, and outcomes related to subclinical peripheral arterial disease in Mexican Americans. His research career has led to over 120 publications in peer-reviewed journals. He has served as the Associate Editor of Catheterization and Cardiovascular Interventions (CCI), Associate Peripheral Arterial Disease Section Editor for SCAI.org, on the ACC Interventional Section writing committee, ACC NCDR PVI Steering committee, XLPAD steering committee and on the editorial board for the Journal of Invasive Cardiology, JSCAI and editorial consultant for the Journal of the American College of Cardiology. He is the co-founder and current president of the San Antonio Interventional Forum (SAIF) which is a regional forum for interventional cardiologists to collaborate and engage in case presentations.

The intersection of his research and clinical interests has led to the creation of the largest cardio-renal symposium in the United States: Cardio-Renal Connections. As co-founder of this meeting, Dr. Prasad has worked to bring together clinicians, nurses, students, researchers, and industry to better address the challenges in management of patients with concomitant heart and kidney disease.

Dr. Summers, Billy S. Guyton Professor Emeritus, is a native of Gulfport Mississippi and graduated from the University of Southern Mississippi magna cum laude in mathematics in 1977. He received his medical degree from the University of Mississippi Medical Center in 1981 after which he entered their residency program in internal medicine. Summers then began graduate studies and completed a research fellowship under Drs Arthur C. Guyton and Thomas G. Coleman in the Department of Physiology and Biophysics. Since 1988 he has been a faculty member at the University of Mississippi Medical Center in various roles including Chairman of the Department of Emergency Medicine. He previously served as the Associate Vice Chancellor for Research and holds joint appointments in the Department of Emergency Medicine and the Department of Physiology and Biophysics and is a Fellow of the American College of Emergency Physicians. He has coauthored over 300 publications and received research awards from the American Heart Association and the Society for Academic Emergency Medicine. He is also the recipient of the prestigious Sebetia Ter International Award for Biomedical Research.

During his career, Dr. Summers has been funded by NIH, NASA and several foundations. He was previously the lead scientist for the NASA Digital Astronaut Project and a member of the advisory team for the NASA Cardiovascular Laboratory.

Dr. Ebbini received his PhD from the University of Illinois at Urbana-Champaign in 1990. He is currently a professor in electrical and computer engineering at the University of Minnesota Twin-Cities. His research interests are in signal and array processing with applications to medical ultrasound. He is a fellow of the IEEE and has been active in several IEEE societies, conferences and journals. Dr. Ebbini also served as the President of the International Society for Therapeutic Ultrasound (2012 – 2015) in addition to being a founding member of the Society in 2001. He contributed to both diagnostic and therapeutic aspects of medical ultrasound, including optimal array pattern synthesis for imaging and therapy, temperature imaging, nonlinear contrast agent imaging, high-speed parallel imaging.

Dr. Ebbini pioneered the concept of dual-mode ultrasound array (DMUA) systems for image-guided surgery and other noninvasive interventions such as transcranial neuromodulation. His research team at Minnesota recently demonstrated the real-time use of this technology in a preclinical model of hypertension in vivo, where they have demonstrated the feasibility of forming precise thermal lesions in the carotid body. The technology has also been used to successfully target/ablate atherosclerotic plaques in the femoral artery in human patients under license from the University of Minnesota. Most recently, Dr. Ebbini has been collaborating with colleagues from Neurosurgery to investigate the use of ablative and neuromodulatory applications of transcranial focused ultrasound (tFUS), including potential treatment of glioblastoma. His laboratory is currently investigating a number of novel approaches involving 3D imaging, real-time ultrasound thermometry in vivo, and self-focusing arrays in the presence of strongly scattering objects.

Dr. Ebbini has served on numerous consulting and advisory panels for governmental and private organizations, including NIH, NSF, and NASA. He was a charter member of the NIH Biomedical Imaging Study Section-B and he currently serves as a consultant to the FDA Center for Devices and Radiological Health. He has also served as an associate editor/editorial board member for several journals and a guest editor of three special issues on therapeutic ultrasound.

Dori has more than 15 years of experience in cardiac and critical care devices and has held positions in Research & Development, Engineering, Clinical, and Marketing.  Her areas of expertise include mechanical circulatory support, fluid management, neuromodulation and hemodynamic monitoring.  Dori is the founder and managing director of D Squared Consulting, providing cross-disciplinary support to some of the global leaders in the medical device industry.

Dori has a BS in Mechanical Engineering from Lehigh University and a MSE in Biomedical Engineering from Purdue University, which is complemented by a decade of field clinical experience.

Rachel has worked in the healthcare industry since 2010. Her expertise is in Market Access, Healthcare Economics, and Medical Coding. Rachel is currently the Director of Field Reimbursement at W.L. Gore in the Medical Products Division.  She previously was the  Head of US Market Access and Healthcare Economics at Tulavi Therapeutics from 2022-2024.  She also served as Sr. Director, National Accounts and Public Policy at Osprey Medical from 2018-2021. Early in her career she was Director at Premier Inc and Avalere Health, leading strategic business development initiatives around value based healthcare delivery and evidence generation for Life Science clients and Universities.

Rachel has a Master of Science in HealthCare Administration from Marymount University and a BBA from Baylor University. She is a Certified Professional Coder through AAPC.